| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96466 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-461
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e80b43133e44ae7fd73fffe9d36c449b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b07e4b8adc2f8f9f797502d7589d3dac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf01c742a5dd03b22cabbee6035d511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_728a910c75596d0acf25d558d0ce12a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1901f4510fde7e029f1ef4b158e50da |
| publicationDate |
2019-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019016827-A1 |
| titleOfInvention |
Method for determining the in vivo interaction mode |
| abstract |
Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10851138-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019194263-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11572391-B2 |
| priorityDate |
2015-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |